Rapid IHC workflow Celerus Diagnostics has a proven fast immunohistochemistry platform (Wave and Wave RPD) that delivers actionable diagnostic results quickly. This positions the company as a potential partner for labs seeking to enhance throughput, reduce turnaround times, and improve intraoperative decision making, creating upsell opportunities for larger pathology labs and hospital systems.

Automation leadership The fully automated Wave RPD system represents a frontier in automated IHC staining, enabling scalable processing with consistent quality. This can be leveraged to target high-volume laboratories, academic centers, and integrated delivery networks looking to standardize operations and reduce labor costs.

Healthcare cost impact By shortening staining time from start to finish to 75 minutes and improving diagnostic workflow, Celerus claims cost reductions and faster patient care. Sales conversations can emphasize total cost of ownership, throughput gains, and potential reimbursement-aligned value in rapid diagnostic pathways.

Growth potential With revenue in a startup-to-mid stage range and a predominantly professional services footprint, there is room to expand into larger clinical laboratories and regional networks. Strategic partnerships or channel partnerships with diagnostic distributors could amplify market reach.

Strategic fit opportunities Target markets include cancer diagnostics, intraoperative pathology, and laboratories requiring rapid IHC results. Potential sales plays include lab optimization projects, upgrades from older IHC platforms, and integration with existing LIS/WIS workflows to demonstrate seamless adoption and measurable performance gains.